Pfizer

Yahoo Finance • 14 hours ago

Activist Starboard buys more Salesforce stock after first demanding change in 2022

By Svea Herbst-Bayliss NEW YORK (Reuters) -Activist Starboard Value, one of the first investors to publicly push Salesforce to make changes three years ago, increased its stake in the U.S. software company by almost 50% in the second quar... Full story

Yahoo Finance • 20 hours ago

Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

New York, USA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight The vitiligo treatment landscape is evolving with a shift tow... Full story

Yahoo Finance • 23 hours ago

Guru Fundamental Report for PFE

Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. This strategy looks for compa... Full story

Yahoo Finance • yesterday

If You Invested $10K In Pfizer Stock 10 Years Ago, How Much Would You Have Now?

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, and sells biopharmaceutical products in the U.S. and internationally. It is se... Full story

Yahoo Finance • yesterday

Terns Pharmaceuticals’ SWOT analysis: obesity drug stock poised for pivotal data

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and other metabolic diseases. The company’s stock has garnered significant attention from analysts and inv... Full story

Yahoo Finance • yesterday

Big Pharma Has a New Vision for Selling Drugs. It’s Going to the Mattresses.

Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen. Continue Reading View Comments... Full story

Yahoo Finance • 2 days ago

Should You Now Consider Selling Your Pfizer (PFE) Shares Before its Too Late?

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks, released its Parnassus Value Equity Fund second-quarter 2025 investor letter. The full letter is available for d... Full story

Yahoo Finance • 2 days ago

AI in Education Market Surges to $5.82 billion by 2030 - Dominated by Microsoft (US), IBM (US), Google (US)

Delray Beach, FL, Aug. 13, 2025 (GLOBE NEWSWIRE) -- According to MarketsandMarkets™, the global AI in Education Market size is anticipated to grow at a CAGR of 17.5% during the forecast period, from USD 2.21 billion in 2024 to USD 5.82 b... Full story

Yahoo Finance • 2 days ago

Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB

Dublin, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Osteoporosis Drugs Market to Reach US$ 308.84 Million by 2033 - 4.33% CAGR Driven by Biologics and Aging Population" report has been added to ResearchAndMarkets.com's offering.... Full story

Yahoo Finance • 3 days ago

Sector Update: Health Care Stocks Advance in Afternoon Trading

Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index up 0.3% and the Health Ca PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 days ago

Pfizer Raises Its Guidance and Analysts Up Their Targets - PFE Stock Looks Cheap

PFIZER, INC. (PFE [https://www.barchart.com/stocks/quotes/PFE/overview]) stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance. It's at just over 8x this year's estimates and 7.8x next year... Full story

Yahoo Finance • 3 days ago

Pfizer/BioNTech may not win FDA renewal for pediatric COVID shot: report

[FDA headquarters in Washington DC.] JHVEPhoto The U.S. Food and Drug Administration (FDA) is unlikely to renew the authorization granted to use Pfizer (NYSE:PFE [https://seekingalpha.com/symbol/PFE]) and BioNTech’s (BNTX [https://seeking... Full story

Yahoo Finance • 3 days ago

Pfizer, Astellas post late-stage trial win for Padcev with Merck’s Keytruda in bladder cancer

[definition of Bladder cancer] Devonyu/iStock via Getty Images Pfizer (NYSE:PFE [https://seekingalpha.com/symbol/PFE]) and Astellas Pharma (OTCPK:ALPMF [https://seekingalpha.com/symbol/ALPMF]) announced on Tuesday that their jointly devel... Full story

Yahoo Finance • 3 days ago

Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda

Company Logo The Global Multiple Myeloma Market is projected to grow from USD 21.78 billion in 2024 to USD 40.41 billion by 2033, at a CAGR of 7.11%. Growth drivers include rising multiple myeloma cases, advances in targeted therapies lik... Full story

Yahoo Finance • 3 days ago

Vitiligo Treatment Strategic Market Research Report 2025-2030 | Increased Psychological and Social Impact of Vitiligo Drives Demand for More Effective Therapies

Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Vitiligo Treatment - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Vitiligo Treatment was estimated at US$1.5 Billion in 20... Full story

Yahoo Finance • 3 days ago

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

Total revenues of €97.6 million compared to €70.8 million in the first half of 2024Cash and cash equivalents of €161.3 million at end of June 2025Further clinical and regulatory progress2025 financial outlook confirmed Saint-Herblain (Fra... Full story

Yahoo Finance • 3 days ago

Valneva publie ses résultats financiers du premier semestre 2025 et fait un point sur ses activités

Chiffre d’affaires de 97,6 millions d’euros contre 70,8 millions d’euros au premier semestre 2024Trésorerie de 161,3 millions d’euros à fin juin 2025Poursuite des avancées cliniques et réglementaires Confirmation des perspectives 2025 Sai... Full story

Yahoo Finance • 4 days ago

Biotech sector slips amid reported return of ousted FDA official

[FDA headquarters in Washington DC.] JHVEPhoto/iStock Editorial via Getty Images Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration vaccine regulator Vinay Prasad w... Full story

Yahoo Finance • 4 days ago

Chronic Inflammatory Demyelinating Polyneuropathy Market Report 2025 | Distribution Channel, Route of Administration, and Region Analysis and Forecast to 2035

Dublin, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The "Chronic Inflammatory Demyelinating Polyneuropathy Market - A Global and Regional Analysis: Focus on Distribution Channel, Route of Administration, and Region - Analysis and Forecast, 2025-20... Full story

Yahoo Finance • 4 days ago

Multiple Myeloma Global and Regional Market Analysis and Forecast Report 2025-2035 | Johnson & Johnson, Sanofi, AbbVie, Bristol-Myers Squibb, Takeda, Pfizer Drive Innovation and Growth

Dublin, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The "Multiple Myeloma Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The gl... Full story